Description
TRZ is a synthetic peptide characterized as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is studied for its interaction with multiple incretin receptor pathways and associated signaling mechanisms.
Research applications of TRZ include investigation of receptor co-activation, ligand selectivity, and intracellular signaling cascades within controlled laboratory settings.
TRZ is supplied exclusively for laboratory research purposes only. It is not approved by the FDA for human or veterinary use and is not intended for diagnostic or therapeutic applications.
